RS58421B1 - Prevencija i lečenje sinukleinopatske i amiloidogene bolesti - Google Patents
Prevencija i lečenje sinukleinopatske i amiloidogene bolestiInfo
- Publication number
- RS58421B1 RS58421B1 RS20190087A RSP20190087A RS58421B1 RS 58421 B1 RS58421 B1 RS 58421B1 RS 20190087 A RS20190087 A RS 20190087A RS P20190087 A RSP20190087 A RS P20190087A RS 58421 B1 RS58421 B1 RS 58421B1
- Authority
- RS
- Serbia
- Prior art keywords
- synucleinopathic
- prevention
- treatment
- amyloidogenic disease
- amyloidogenic
- Prior art date
Links
- 102000009091 Amyloidogenic Proteins Human genes 0.000 title 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 title 1
- 230000003942 amyloidogenic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/915,214 US8697082B2 (en) | 2002-11-01 | 2004-08-09 | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US11/185,907 US8506959B2 (en) | 2002-11-01 | 2005-07-19 | Prevention and treatment of synucleinopathic and amyloidogenic disease |
EP05783732.0A EP1793855B2 (en) | 2004-08-09 | 2005-08-09 | Prevention and treatment of synucleinopathic and amyloidogenic disease |
PCT/US2005/028166 WO2006020581A2 (en) | 2004-08-09 | 2005-08-09 | Prevention and treatment of synucleinopathic and amyloidogenic disease |
Publications (2)
Publication Number | Publication Date |
---|---|
RS58421B1 true RS58421B1 (sr) | 2019-04-30 |
RS58421B2 RS58421B2 (sr) | 2022-05-31 |
Family
ID=35908081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20190087A RS58421B2 (sr) | 2004-08-09 | 2005-08-09 | Prevencija i lečenje sinukleinopatske i amiloidogene bolesti |
Country Status (22)
Country | Link |
---|---|
US (2) | US8506959B2 (sr) |
EP (2) | EP3369433A1 (sr) |
JP (1) | JP5211290B2 (sr) |
KR (2) | KR20070042566A (sr) |
AU (1) | AU2005273969B2 (sr) |
BR (1) | BRPI0514199A (sr) |
CA (1) | CA2576672C (sr) |
CY (1) | CY1121408T1 (sr) |
DK (1) | DK1793855T4 (sr) |
ES (1) | ES2705586T5 (sr) |
HR (1) | HRP20190008T4 (sr) |
HU (1) | HUE041974T2 (sr) |
IL (2) | IL235725B (sr) |
LT (1) | LT1793855T (sr) |
ME (1) | ME03302B (sr) |
NO (1) | NO20071267L (sr) |
NZ (1) | NZ553621A (sr) |
PL (1) | PL1793855T5 (sr) |
PT (1) | PT1793855T (sr) |
RS (1) | RS58421B2 (sr) |
SI (1) | SI1793855T2 (sr) |
WO (1) | WO2006020581A2 (sr) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040146521A1 (en) * | 1999-06-01 | 2004-07-29 | Schenk Dale B. | Prevention and treatment of synucleinopathic disease |
US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
US9034337B2 (en) * | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US8697082B2 (en) * | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US7358331B2 (en) * | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
EA013752B1 (ru) | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний |
EP2436696B8 (en) | 2007-01-05 | 2017-12-13 | University of Zurich | Anti-beta-amyloid antibody and uses thereof |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
PT3067066T (pt) * | 2007-02-23 | 2019-06-17 | Univ California | Prevenção e tratamento da doença sinucleinopática e amiloidogénica |
DK3067066T3 (da) * | 2007-02-23 | 2019-05-20 | Prothena Biosciences Ltd | Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom |
US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
CN101265297B (zh) * | 2007-03-15 | 2012-08-15 | 中国科学院上海生命科学研究院 | α-突触核蛋白与Sph1的相互作用位点及其在筛选帕金森症药物中的应用 |
AU2008345022B2 (en) * | 2007-12-28 | 2014-11-06 | Prothena Biosciences Limited | Treatment and prophylaxis of amyloidosis |
AU2015249034B2 (en) * | 2007-12-28 | 2017-07-27 | Prothena Biosciences Limited | Treatment and prophylaxis of amyloidosis |
AT506535B1 (de) | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
US8546532B2 (en) * | 2008-04-17 | 2013-10-01 | Declion Pharmaceuticals, Inc. | Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders |
LT2282758T (lt) * | 2008-04-29 | 2019-03-12 | Bioarctic Ab | Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams |
US8940276B2 (en) | 2008-12-19 | 2015-01-27 | Biogen Idec International Neuroscience Gmbh | Human anti-alpha-synuclein antibodies |
AT508638B1 (de) * | 2009-08-21 | 2011-08-15 | Affiris Ag | Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien |
US8632776B2 (en) | 2010-02-26 | 2014-01-21 | Bioarctic Neuroscience Ab | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's disease, dementia with lewy bodies and other α-synucleinopathies |
GB201008682D0 (en) * | 2010-05-25 | 2010-07-07 | Vib Vzw | Epitope tag for affinity based applications |
CA3077910A1 (en) | 2010-11-17 | 2012-05-24 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
KR101308898B1 (ko) * | 2011-02-08 | 2013-09-23 | 건국대학교 산학협력단 | 신규 항-α-시누클레인 단일클론항체 및 이를 이용한 ELISA 시스템 |
CN103764166B (zh) * | 2011-06-22 | 2017-10-24 | 通用医疗公司 | 蛋白质病的治疗 |
PT2723379T (pt) * | 2011-06-23 | 2018-11-14 | Univ Of Zuerich | Moléculas de ligação anti-alfa-sinucleína |
CN104334184B (zh) | 2011-10-28 | 2017-12-29 | 普罗典娜生物科学有限公司 | 识别α‑突触核蛋白的人源化抗体 |
CA2863953A1 (en) | 2012-01-27 | 2013-08-01 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
KR20140077567A (ko) * | 2012-12-14 | 2014-06-24 | 건국대학교 산학협력단 | 세포외 α-시누클레인 제거와 관련된 질환 치료용 조성물 및 그 치료제 스크리닝 방법 |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
WO2015075635A2 (en) | 2013-11-19 | 2015-05-28 | Prothena Biosciences Limited | Monitoring immunotherapy of lewy body disease from constipation symptoms |
WO2015155694A1 (en) * | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック, インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
DK3341725T3 (da) * | 2015-08-25 | 2021-09-06 | Prothena Biosciences Ltd | Fremgangsmåder til detektering af phosphoryleret alpha-synuklein |
EP3207925A1 (en) * | 2016-02-22 | 2017-08-23 | Universität Wien | Compound for use in the prevention and treatment of neurodegenerative diseases |
PT3383381T (pt) * | 2015-11-30 | 2020-07-03 | Universita¿T Wien | Composto para uso na prevenção e tratamento de doenças neurodegenerativas |
CN116120445A (zh) | 2016-06-02 | 2023-05-16 | 麦迪穆有限责任公司 | 针对α-突触核蛋白的抗体及其用途 |
WO2018091444A1 (en) | 2016-11-15 | 2018-05-24 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
WO2018109058A1 (en) * | 2016-12-16 | 2018-06-21 | H. Lundbeck A/S | Agents, uses and methods |
US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
SG11202001281WA (en) | 2017-08-22 | 2020-03-30 | Biogen Ma Inc | Pharmaceutical compositions containing anti-beta amyloid antibodies |
CA3076313A1 (en) | 2017-09-28 | 2019-04-04 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
CA3088112A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
BR112022021203A2 (pt) | 2020-04-24 | 2022-12-06 | Hoffmann La Roche | Modulação de enzima e via com compostos sulfidrila e seus derivados |
JP7337959B2 (ja) | 2020-06-26 | 2023-09-04 | バイオアークティック アーベー | α-シヌクレインプロトフィブリル結合抗体 |
KR102513116B1 (ko) | 2021-06-03 | 2023-03-22 | 고려대학교 산학협력단 | 알파시뉴클레인-금나노입자 복합체, 이의 제조방법 및 이를 이용한 약물 스크리닝 방법 |
Family Cites Families (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
DE3521994A1 (de) | 1985-06-20 | 1987-01-02 | Bayer Ag | N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
US4883666A (en) * | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5583112A (en) | 1987-05-29 | 1996-12-10 | Cambridge Biotech Corporation | Saponin-antigen conjugates and the use thereof |
US6093406A (en) | 1988-06-02 | 2000-07-25 | The United States Of America As Represented By The Secretary Of The Army | Vaccine for induction of immunity to malaria |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5576184A (en) | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
ES2055785T3 (es) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5753624A (en) | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
JP2980677B2 (ja) | 1990-04-27 | 1999-11-22 | マクマイケル,ジョン | 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物 |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
ES2109945T3 (es) | 1990-06-01 | 1998-02-01 | Chiron Corp | Composiciones y procedimientos para identificar moleculas biologicamente activas. |
US5593970A (en) | 1990-06-11 | 1997-01-14 | Biochem Pharma Inc. | Heterocyclic anthracycline analogs |
AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5780587A (en) | 1990-08-24 | 1998-07-14 | President And Fellows Of Harvard College | Compounds and methods for inhibiting β-protein filament formation and neurotoxicity |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
EP0592668B1 (en) | 1991-07-03 | 1999-03-10 | Kanebo, Ltd. | Method and device for the manufacture of a thermoplastic polyurethane elastomer |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
WO1993006121A1 (en) | 1991-09-18 | 1993-04-01 | Affymax Technologies N.V. | Method of synthesizing diverse collections of oligomers |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
HUT72495A (en) | 1992-10-01 | 1996-05-28 | Cold Spring Harbor Lab | Complex combinatorial chemical libraries encoded with tags |
US5958883A (en) | 1992-09-23 | 1999-09-28 | Board Of Regents Of The University Of Washington Office Of Technology | Animal models of human amyloidoses |
US5674703A (en) | 1992-12-02 | 1997-10-07 | Woo; Savio L. C. | Episomal vector systems and related methods |
EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
CA2115900A1 (en) | 1993-02-22 | 1994-08-23 | Gerald W. Becker | Pharmaceutical screens and antibodies |
JPH09501936A (ja) | 1993-08-26 | 1997-02-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置 |
WO1995006407A1 (en) | 1993-08-30 | 1995-03-09 | The Regents Of The University Of California | Novel component of amyloid in alzheimer's disease and methods for use of same |
AU698962B2 (en) | 1993-09-14 | 1998-11-12 | Epimmune, Inc. | Alteration of immune response using pan DR-binding peptides |
GB2298863B (en) | 1993-11-02 | 1998-03-11 | Affymax Tech Nv | Apparatus and process for the synthesis of diverse compounds especially for generating and screening compound libraries |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
US7473423B2 (en) * | 1994-04-29 | 2009-01-06 | Mayo Foundation For Medical Education And Research | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
CA2189634A1 (en) | 1994-05-06 | 1995-11-16 | John J. Baldwin | Combinatorial dihydrobenzopyran library |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
US5663046A (en) | 1994-06-22 | 1997-09-02 | Pharmacopeia, Inc. | Synthesis of combinatorial libraries |
EP1181937A3 (en) | 1994-08-09 | 2004-02-04 | Cytrx Corporation | Novel vaccine adjuvant and vaccine |
US5589154A (en) | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
US5807741A (en) | 1995-07-20 | 1998-09-15 | Brown; Douglas Richard | Neutralizing monoclonal antibody against botulinum neurotoxin serotype F |
AU705688B2 (en) | 1995-11-10 | 1999-05-27 | Cytogen Corporation | Peptides which enhance transport across tissues and methods of identifying and using the same |
AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
CA2242092C (en) | 1996-12-03 | 2003-03-25 | Northern Telecom Limited | System connecting remote agents over standard telephone lines |
EP1005368B1 (en) | 1997-03-10 | 2009-09-02 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants |
WO1998059050A1 (en) | 1997-06-25 | 1998-12-30 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | Cloning of a gene mutation for parkinson's disease |
US7078191B1 (en) | 1997-08-01 | 2006-07-18 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6923964B1 (en) * | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
WO1999040191A1 (fr) | 1998-02-09 | 1999-08-12 | Boehringer Ingelheim International Gmbh | Adn ou genes contribuant au developpement de la maladie de parkinson |
WO1999050300A1 (en) | 1998-03-30 | 1999-10-07 | The Trustees Of The University Of Pennsylvania | Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders |
CN1344275A (zh) | 1998-05-21 | 2002-04-10 | 田纳西州立大学研究股份有限公司 | 用淀粉样蛋白抗体除去淀粉样蛋白的方法 |
US6184351B1 (en) | 1998-09-25 | 2001-02-06 | Amgen Inc. | α-synuclein super-mutants accelerate α-synuclein aggregation |
AU6288499A (en) | 1998-10-06 | 2000-04-26 | Regents Of The University Of California, The | Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease |
US6172122B1 (en) | 1998-12-17 | 2001-01-09 | The Lubrizol Corporation | Stable emulsions from gelled overbased substrates with surfactants and aqueous liquids |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US20040146521A1 (en) | 1999-06-01 | 2004-07-29 | Schenk Dale B. | Prevention and treatment of synucleinopathic disease |
CA2378953A1 (en) | 1999-07-27 | 2001-02-01 | Abgenix, Inc. | Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
GB9924513D0 (en) | 1999-10-15 | 1999-12-15 | Novartis Ag | Organic compounds |
US6557129B1 (en) | 1999-11-23 | 2003-04-29 | Janusz Rajski | Method and apparatus for selectively compacting test responses |
US20020094335A1 (en) | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
WO2001053457A2 (en) | 2000-01-21 | 2001-07-26 | University Of Connecticut Health Center | Vaccines against neurodegenerative disorders |
US7276643B2 (en) | 2000-02-18 | 2007-10-02 | The Regents Of The University Of California | Transgenic animals, cell lines derived therefrom, and methods for screening for anti-amyloidogenic agents |
MXPA02007796A (es) | 2000-02-21 | 2003-12-08 | Pharmexa As | Metodo novedoso para la disminucion de cuerpos amiloides. |
EP1259251B1 (en) | 2000-02-21 | 2005-10-19 | Pharmexa A/S | Novel method for down-regulation of amyloid |
EP1282699B1 (en) | 2000-05-04 | 2012-11-21 | Sarepta Therapeutics, Inc. | Splice-region antisense composition and method |
WO2002003911A2 (en) | 2000-07-07 | 2002-01-17 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
AU2001271865C1 (en) | 2000-07-07 | 2006-12-07 | Panacea Pharmaceuticals, Inc. | Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US20020160394A1 (en) | 2001-01-24 | 2002-10-31 | Bayer Corporation | Regulation of transthyretin to treat obesity |
US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
US20020197258A1 (en) | 2001-06-22 | 2002-12-26 | Ghanbari Hossein A. | Compositions and methods for preventing protein aggregation in neurodegenerative diseases |
MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
WO2003037712A1 (fr) * | 2001-11-01 | 2003-05-08 | Ishigaki Company Limited | Dispositif de propulsion par jet d'eau utilise dans un bateau |
CA2468088A1 (en) | 2001-11-20 | 2003-05-30 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
WO2003045128A2 (en) | 2001-11-21 | 2003-06-05 | New York University | SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO |
GB0203446D0 (en) | 2002-02-14 | 2002-04-03 | Univ Lancaster | Detection and/or monitoring of synuclein-related diseases |
GB0216972D0 (en) | 2002-07-22 | 2002-08-28 | Univ Lancaster | Peptides and peptide derivaties for the treatment of &-synuclein-related diseases |
WO2004030622A2 (en) | 2002-09-30 | 2004-04-15 | Auburn University | Method of isolation and self-assembly of small protein particles from blood and other biological materials |
US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
US8697082B2 (en) | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
EP2361928B1 (en) | 2003-05-19 | 2017-04-26 | Prothena Biosciences Limited | Truncated fragments of alpha-synuclein in Lewy body disease |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
US7674599B2 (en) * | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
WO2005108423A1 (en) | 2004-05-11 | 2005-11-17 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
EA013752B1 (ru) | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний |
US20080300204A1 (en) | 2005-07-19 | 2008-12-04 | University Of Rochester | Alpha-Synuclein Antibodies and Methods Related Thereto |
WO2007021255A1 (en) | 2005-08-09 | 2007-02-22 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
DK3067066T3 (da) | 2007-02-23 | 2019-05-20 | Prothena Biosciences Ltd | Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom |
US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US20150095800A1 (en) | 2013-09-30 | 2015-04-02 | Microsoft Corporation | Prioritizing communications based on communication patterns |
-
2005
- 2005-07-19 US US11/185,907 patent/US8506959B2/en active Active
- 2005-08-09 AU AU2005273969A patent/AU2005273969B2/en active Active
- 2005-08-09 KR KR1020077004883A patent/KR20070042566A/ko not_active Application Discontinuation
- 2005-08-09 WO PCT/US2005/028166 patent/WO2006020581A2/en active Application Filing
- 2005-08-09 BR BRPI0514199-0A patent/BRPI0514199A/pt not_active Application Discontinuation
- 2005-08-09 EP EP18165937.6A patent/EP3369433A1/en not_active Withdrawn
- 2005-08-09 PL PL05783732T patent/PL1793855T5/pl unknown
- 2005-08-09 CA CA2576672A patent/CA2576672C/en active Active
- 2005-08-09 DK DK05783732.0T patent/DK1793855T4/da active
- 2005-08-09 HU HUE05783732A patent/HUE041974T2/hu unknown
- 2005-08-09 NZ NZ553621A patent/NZ553621A/en not_active IP Right Cessation
- 2005-08-09 PT PT05783732T patent/PT1793855T/pt unknown
- 2005-08-09 ME MEP-2019-1A patent/ME03302B/me unknown
- 2005-08-09 ES ES05783732T patent/ES2705586T5/es active Active
- 2005-08-09 JP JP2007525714A patent/JP5211290B2/ja active Active
- 2005-08-09 KR KR1020137009153A patent/KR101340417B1/ko active IP Right Grant
- 2005-08-09 SI SI200532239T patent/SI1793855T2/sl unknown
- 2005-08-09 US US11/660,015 patent/US20100031377A1/en not_active Abandoned
- 2005-08-09 HR HRP20190008TT patent/HRP20190008T4/hr unknown
- 2005-08-09 EP EP05783732.0A patent/EP1793855B2/en active Active
- 2005-08-09 LT LTEP05783732.0T patent/LT1793855T/lt unknown
- 2005-08-09 RS RS20190087A patent/RS58421B2/sr unknown
-
2007
- 2007-01-30 IL IL235725A patent/IL235725B/en active IP Right Grant
- 2007-01-30 IL IL181061A patent/IL181061A/en active IP Right Grant
- 2007-03-08 NO NO20071267A patent/NO20071267L/no not_active Application Discontinuation
-
2019
- 2019-02-13 CY CY20191100196T patent/CY1121408T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS58421B2 (sr) | Prevencija i lečenje sinukleinopatske i amiloidogene bolesti | |
EP1910829A4 (en) | PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE | |
EP2118300A4 (en) | PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGEN DISEASES | |
AU2003290548A8 (en) | Prevention and treatment of synucleinopathic disease | |
ZA200700771B (en) | Vaccine for prevention and treatment of HIV-infection | |
EP1968607A4 (en) | TREATMENT OF CANCER AND OTHER DISEASES | |
IL178996A0 (en) | Thienopyridinone compounds and methods of treatment | |
ZA200701531B (en) | Prevention and treatment of synucleinopathic and amyloidogenic disease | |
GB0610350D0 (en) | prevention and/or treatment of neuodegenerative disorders | |
IL182436A0 (en) | Thienopyridinone compounds and methods of treatment | |
EP1865972A4 (en) | TREATMENT OR PREVENTION OF CANCER AND PRECANCEROUS DISORDERS | |
EP1789047A4 (en) | PROCESS FOR TREATING DISEASES USING NALMEFENE AND ITS ANALOGUES | |
HK1184169A1 (zh) | 共核蛋白病和致澱粉樣病的預防和治療 | |
EP1817039A4 (en) | TREATMENT AND PREVENTION OF EPILEPSY | |
EP1773882A4 (en) | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH SIGLEC-6 | |
GB0320238D0 (en) | Treatment of disease | |
GB2441094B (en) | Methods for treatment and prevention of infection | |
GB0419828D0 (en) | The treatment of inflammatroy disorders and pain | |
GB0414428D0 (en) | Compounds and methods of treatment | |
GB0407710D0 (en) | Treatment of diseases | |
GB201010682D0 (en) | Methods for treatment and prevention of infection | |
GB0510257D0 (en) | Methods for treatment and prevention of infection | |
GB0612749D0 (en) | Treatment and/or prevention of pain |